D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 47 Citations 6,644 180 World Ranking 3511 National Ranking 302

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Immune system
  • Antibody

Her primary areas of investigation include Immunology, Internal medicine, Tissue microarray, Antigen and Colorectal cancer. As part of one scientific family, Lindy G. Durrant deals mainly with the area of Immunology, narrowing it down to issues related to the Cancer, and often Clinical trial. Her Internal medicine research incorporates elements of Endocrinology and Oncology.

Her studies deal with areas such as Cancer research, MHC class I, Survival analysis and Immune system as well as Tissue microarray. Her biological study spans a wide range of topics, including Antibody and Pathology. Her work deals with themes such as Breast cancer, Nottingham Prognostic Index, Angiogenesis and Cytokine, which intersect with Pathology.

Her most cited work include:

  • Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. (181 citations)
  • Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? (172 citations)
  • Defining the critical hurdles in cancer immunotherapy (132 citations)

What are the main themes of her work throughout her whole career to date?

Lindy G. Durrant mainly investigates Immunology, Antigen, Antibody, Monoclonal antibody and Immune system. The various areas that Lindy G. Durrant examines in her Immunology study include Cytotoxic T cell and Cancer, Colorectal cancer. Her work carried out in the field of Antigen brings together such families of science as Pathology, Virology and Vaccination.

Her Pathology research focuses on Breast cancer and how it connects with Immunohistochemistry. Her Antibody research integrates issues from Biochemistry and Glycan. Her study looks at the relationship between Immune system and topics such as Cancer research, which overlap with Tissue microarray, Cancer immunotherapy and CD59.

She most often published in these fields:

  • Immunology (36.63%)
  • Antigen (33.17%)
  • Antibody (30.20%)

What were the highlights of her more recent work (between 2013-2021)?

  • Cancer research (19.80%)
  • Cancer (20.30%)
  • Immune system (23.27%)

In recent papers she was focusing on the following fields of study:

Cancer research, Cancer, Immune system, Antibody and Epitope are her primary areas of study. Lindy G. Durrant has included themes like Enzyme, Colorectal cancer, Ovarian cancer and Cancer immunotherapy in her Cancer research study. Her Cancer study combines topics in areas such as Self-Antigens, Oncology, Glycoprotein and Pathology.

Lindy G. Durrant does research in Antibody, focusing on Monoclonal antibody specifically. Immunology and Antigen are the areas that her Epitope study falls under. The T cell research she does as part of her general Immunology study is frequently linked to other disciplines of science, such as Citrullination, therefore creating a link between diverse domains of science.

Between 2013 and 2021, her most popular works were:

  • Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell–Mediated Antitumor Immunity (39 citations)
  • Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer. (30 citations)
  • Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. (29 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Immune system
  • Antibody

Lindy G. Durrant focuses on Epitope, Immunotherapy, Immune system, Immunology and T cell. To a larger extent, Lindy G. Durrant studies Antigen with the aim of understanding Epitope. The Antigen study which covers Cancer that intersects with Adoptive cell transfer, Immunity, Cell and Progression-free survival.

Her research in Immunotherapy intersects with topics in Cancer cell, Antibody and Pharmacology. In Immune system, she works on issues like Cancer research, which are connected to Major histocompatibility complex, Colorectal cancer and Cell nucleus. Her Immunology study frequently links to other fields, such as Autophagy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

Nicholas F.S. Watson;Judith M. Ramage;Zahra Madjd;Ian Spendlove.
International Journal of Cancer (2006)

277 Citations

Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

Ekaterina S. Jordanova;Arko Gorter;Ouissam Ayachi;Frans Prins.
Clinical Cancer Research (2008)

262 Citations

Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients

Nicholas F.S. Watson;Nicholas F.S. Watson;Ian Spendlove;Zahra Madjd;Roger McGilvray.
International Journal of Cancer (2006)

198 Citations

NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting

Roger W. McGilvray;Robert A. Eagle;Nicholas F.S. Watson;Ahmad Al-Attar.
Clinical Cancer Research (2009)

189 Citations

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer

Jonathan A D Simpson;Ahmad Al-Attar;Nicholas F S Watson;John H Scholefield.
Gut (2010)

186 Citations

Defining the critical hurdles in cancer immunotherapy

Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal.
Journal of Translational Medicine (2011)

179 Citations

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

Zahra Madjd;Ian Spendlove;Sarah E. Pinder;Ian O. Ellis.
International Journal of Cancer (2005)

169 Citations

The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin.

S. A. Watson;L. G. Durrant;J. D. Crosbie;D. L. Morris.
International Journal of Cancer (1989)

156 Citations

Gastrin: growth enhancing effects on human gastric and colonic tumour cells.

S Watson;L Durrant;D Morris.
British Journal of Cancer (1989)

146 Citations

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

Timothy J. Duncan;Ahmad Al-Attar;Phil Rolland;Ian V. Scott.
Clinical Cancer Research (2008)

142 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Lindy G. Durrant

Ekaterina S. Jordanova

Ekaterina S. Jordanova

Vrije Universiteit Amsterdam

Publications: 42

Ian O. Ellis

Ian O. Ellis

University of Nottingham

Publications: 39

Emad A. Rakha

Emad A. Rakha

University of Nottingham

Publications: 30

Andrew R. Green

Andrew R. Green

University of Nottingham

Publications: 29

Federico Garrido

Federico Garrido

University of Granada

Publications: 25

Soldano Ferrone

Soldano Ferrone

Harvard University

Publications: 24

Sjoerd H. van der Burg

Sjoerd H. van der Burg

Leiden University Medical Center

Publications: 23

Chi-Huey Wong

Chi-Huey Wong

Scripps Research Institute

Publications: 19

Arko Gorter

Arko Gorter

Leiden University Medical Center

Publications: 17

Marij J. P. Welters

Marij J. P. Welters

Leiden University Medical Center

Publications: 17

Gert Jan Fleuren

Gert Jan Fleuren

Leiden University Medical Center

Publications: 17

Bernard A. Fox

Bernard A. Fox

Earle A. Chiles Research Institute

Publications: 17

David L. Morris

David L. Morris

University of New South Wales

Publications: 16

Dorothee Herlyn

Dorothee Herlyn

The Wistar Institute

Publications: 15

Francisco Ruiz-Cabello

Francisco Ruiz-Cabello

University of Granada

Publications: 14

Toshihiko Torigoe

Toshihiko Torigoe

Sapporo Medical University

Publications: 14

Trending Scientists

Andy Schürr

Andy Schürr

Technical University of Darmstadt

Marcelo H. Ang

Marcelo H. Ang

National University of Singapore

Marcel Mayor

Marcel Mayor

University of Basel

S. Samar Hasnain

S. Samar Hasnain

University of Liverpool

Etienne Snoeck

Etienne Snoeck

Centre national de la recherche scientifique, CNRS

Peter V. Kharchenko

Peter V. Kharchenko

Harvard University

Hideyuki Doi

Hideyuki Doi

University of Hyogo

Brenda N. Bonnett

Brenda N. Bonnett

University of Guelph

Ann-Bin Shyu

Ann-Bin Shyu

The University of Texas Health Science Center at Houston

David J. Burdige

David J. Burdige

Old Dominion University

Michael A. Matar

Michael A. Matar

Ben-Gurion University of the Negev

Peter D. Balsam

Peter D. Balsam

Columbia University

Mark R. Dixon

Mark R. Dixon

University of Illinois at Chicago

Anders Ekbom

Anders Ekbom

Karolinska Institute

Luigi Tavazzi

Luigi Tavazzi

University of Ferrara

Lisa R. Metsch

Lisa R. Metsch

Columbia University

Something went wrong. Please try again later.